Non Hodgkin Lymphoma Clinical Trial
Ifosfamide/Carboplatin/Etoposide/Rituxan Followed by Zevalin in Relapsed/Refractory Intermediate Grade B-Cell Lymphoma
Summary
In this Multicenter trial, we will evaluate the feasibility, toxicity, and efficacy of treatment with 90Y Zevalin following a short course of salvage chemotherapy in patients with relapsed/refractory intermediate grade B-cell non-Hodgkin's lymphoma.
Full Description
Upon determination of eligibility, patients will receive:
Ifosfamide + Carboplatin + Etoposide + Rituximab
Patients showing no response to this combination regimen will receive 90Y Zevalin after two cycles or when progression is clearly documented. In responding patients, four cycles will be administered, followed by 90Y Zevalin.
Eligibility Criteria
Inclusion Criteria:
To be included in this study, you must meet the following criteria:
Intermediate grade CD20-positive B-cell non-Hodgkin's lymphoma
Persistent lymphoma after one or two previous chemotherapy regimens
Patients should not be considered candidates for high-dose chemotherapy
Ability to perform activities of daily living with assistance
Measurable or evaluable disease
Age > 18 years
Adequate bone marrow, liver and kidney function
Exclusion Criteria:
You cannot participate in this study if any of the following apply to you:
Patients with impaired bone marrow reserve
Female patients who are pregnant or lactating
Serious active infection at the time of treatment
Any other serious underlying condition
Brain or meningeal) with lymphoma
HIV or AIDS-related lymphoma
Received external beam radiation therapy to > 25% of active bone marrow.
History of other cancers, either active or treated
Please note: There are additional inclusion/exclusion criteria. The study center will determine if you meet all of the criteria. If you do not qualify for the trial, study personnel will explain the reasons. If you do qualify, study personnel will explain the trial in detail and answer any questions you may have.
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
Nashville Tennessee, 37023, United States
How clear is this clinincal trial information?
Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.